Clinical Trial Search

Primary: Change in HbA1c From Baseline to Week 26 — -1.55; -0.92; -1.23 percentage of total hemoglobin — p=<.0001

Primary: Number of Participants With Adverse Events — 82; 61; 79; 64 participants

Primary: Change From Baseline in Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period — 43.21 Percent reduction

Primary: Mean Change in Number of Inflammatory Lesions From Baseline to Week 12 — .83; -3.13 lesions — p=0.15

Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 28; 34; 30 participants — p=0.0002

Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 52.4 percentage of subjects

Primary: Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of…

Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8) — -5.21; -7.49; -9.46; -11.90 mm Hg

Primary: Achievement of Castration and Maintenance of Castration — 97.5 percentage of enrolled patients

Primary: Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)

Primary: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion — 657.85; 590.54 days — p=0.0005

Primary: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) — 245…

Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…

Primary: Percentage of Subjects Experiencing Adverse Events (AEs) — 51.5 percentage of participants

Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo — -3.45; -3.37; -2.48 units on a scale